Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China

被引：0
|
作者：
Meiling Huang
Changjiao Yan
Jingjing Xiao
Ting Wang
Rui Ling
机构：
[1] The Fourth Military Medical University,Department of Thyroid, Breast, and Vascular Surgery, Xijing Hospital
来源：
Diagnostic Pathology | / 14卷
关键词：
BRAF V600E mutation; TERT mutation; NRAS mutation; Co-mutations; Papillary thyroid carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
    Kim, Min Jhi
    Kim, Jin Kyong
    Kim, Gi Jeong
    Kang, Sang-Wook
    Lee, Jandee
    Jeong, Jong Ju
    Chung, Woong Youn
    Kim, Daham
    Nam, Kee-Hyun
    CANCERS, 2022, 14 (19)
  • [22] High preponderance of BRAF V600E mutation in papillary thyroid carcinoma (PTC) among Filipinos: A clinicopathologic study
    Espiritu, G. A.
    Ang, D.
    VIRCHOWS ARCHIV, 2017, 471 : S254 - S254
  • [23] Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
    Szymonek, Monika
    Kowalik, Artur
    Kopczynski, Janusz
    Gasior-Perczak, Danuta
    Palyga, Iwona
    Walczyk, Agnieszka
    Gadawska-Juszczyk, Klaudia
    Plusa, Agnieszka
    Mezyk, Ryszard
    Chrapek, Magdalena
    Gozdz, Stanislaw
    Kowalska, Aldona
    ONCOTARGET, 2017, 8 (43) : 74897 - 74909
  • [24] Presence of BRAF V600E in very early stages of papillary thyroid carcinoma
    Ugolini, Clara
    Giannini, Riccardo
    Lupi, Cristiana
    Salvatore, Giuliana
    Miccoli, Paolo
    Proietti, Agnese
    Elisei, Rossella
    Santoro, Massimo
    Basolo, Fulvio
    THYROID, 2007, 17 (05) : 381 - 388
  • [25] Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality
    Liu, Rengyun
    Bishop, Justin
    Zhu, Guangwu
    Zhang, Tao
    Ladenson, Paul W.
    Xing, Mingzhao
    JAMA ONCOLOGY, 2017, 3 (02) : 202 - 208
  • [26] Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
    Ali, Siraj M.
    He, Je
    Carson, Wade
    Stephens, Phil J.
    Fiorillo, Joseph
    Lipson, Doron
    Palmer, Gary A.
    Ross, Jeffrey S.
    Miller, Vincent A.
    Sharman, Jeffrey
    CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 343 - 348
  • [27] Questioning the Role of BRAF V600E as a Prognostic Indicator in Papillary Thyroid Carcinoma
    Javid, Mahsa
    ANNALS OF SURGICAL ONCOLOGY, 2025, : 3060 - 3061
  • [28] Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population
    Brzezianska, Ewa
    Pastuszak-Lewandoska, Dorota
    Wojciechowska, Katarzyna
    Migdalska-Sek, Monika
    Cyniak-Magierska, Anna
    Nawrot, Ewa
    Lewinski, Andrzej
    NEUROENDOCRINOLOGY LETTERS, 2007, 28 (04) : 351 - 359
  • [29] The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma
    Lin, Zi-Mei
    Yan, Cao-Xin
    Song, Yue
    Hong, Yu-Rong
    Wen, Qing
    Xu, Yong-Yuan
    Pan, Min-Qiang
    Ye, Qin
    Huang, Pin-Tong
    JOURNAL OF THORACIC DISEASE, 2019, 11 (12) : 5071 - 5078
  • [30] Lack of MAPK activation in papillary thyroid carcinoma with BRAF V600E mutation
    Zuo, Hui
    Nakamura, Yasushi
    Yasuoka, Hironao
    Nakamura, Misa
    Mori, Ichiro
    Miyauchi, Akira
    Kakudo, Kennichi
    CANCER RESEARCH, 2006, 66 (08)
12345